Bone Therapeutics to End Phase III PREOB Study
The Data and Safety Monitoring Board recommended discontinuation of the Phase III hip osteonecrosis study of Bone Therapeutics' PREOB viscosupplement, following interim analysis of results. Nov 06, 2018